

Appl. No. : 09 603,665  
Filed : June 23, 2000

**IN THE CLAIMS:**

46. (Amended) An isolated, purified, or recombinant polypeptide comprising a contiguous span of at least 6 amino acids of SEQ ID No 5, wherein said continuous span includes:

- at least 1 of the amino acid positions 1 to 1629 of the SEQ ID No 5; or
- an amino acid selected from the group consisting of an asparagine at amino acid position 1694 of SEQ ID No 5, a valine at amino acid position 1854 of SEQ ID No 5, an asparagine at amino acid position 1967 of SEQ ID No 5, a glutamic acid at amino acid position 2017 of SEQ ID No 5, and an alanine at amino acid position 2050 of SEQ ID No 5.

47. (Amended) An isolated or purified antibody composition capable of selectively binding to an epitope-containing fragment of a polypeptide according to claim 46, wherein said epitope comprises:

- at least 1 of the amino acid positions 1 to 1629 of the SEQ ID NO 5; or
- an amino acid selected from the group consisting of an asparagine at amino acid position 1694 of SEQ ID No 5, a valine at amino acid position 1854 of SEQ ID No 5, an asparagine at amino acid position 1967 of SEQ ID No 5, a glutamic acid at amino acid position 2017 of SEQ ID No 5, and an alanine at amino acid position 2050 of SEQ ID No 5.

**Please add the following new claims:**

65. (New) A composition comprising an isolated and purified polypeptide, wherein said polypeptide has an amino acid sequence comprising at least 10 contiguous amino acids of SEQ ID NO:5 spanning position(s) selected from the group consisting of:

- a) 1 to 200;
- b) 201 to 400;
- c) 401 to 600;

**Appl. No.** : 09/603,665  
**Filed** : June 23, 2000

- d) 601 to 800;
- e) 801 to 1000;
- f) 1001 to 1200;
- g) 1201 to 1400;
- h) 1400 to 1629;
- i) 1694, wherein position 1694 is an asparagine;
- j) 1854, wherein position 1854 is a valine;
- k) 1967, wherein position 1967 is an asparagine;
- l) 2017, wherein position 2017 is a glutamic acid; and,
- m) 2050, wherein position 2050 is an alanine.

66. (New) A polypeptide of claim 65, wherein said polypeptide is at least 20 amino acids in length and has an amino acid sequence comprising at least 10 contiguous amino acids of SEQ ID NO:5 spanning position(s) selected from the group consisting of:

- a) 1 to 200;
- b) 201 to 400;
- c) 401 to 600;
- d) 601 to 800;
- e) 801 to 1000;
- f) 1001 to 1200;
- g) 1201 to 1400;
- h) 1400 to 1629;
- i) 1694, wherein position 1694 is an asparagine;

**Appl. No.** : 09.603,665  
**Filed** : June 23, 2000

- j) 1854, wherein position 1854 is a valine;
- k) 1967, wherein position 1967 is an asparagine;
- l) 2017, wherein position 2017 is a glutamic acid; and,
- m) 2050, wherein position 2050 is an alanine.

67. (New) A polypeptide of claim 66, wherein said polypeptide is at least 50 amino acids in length and has an amino acid sequence comprising at least 10 contiguous amino acids of SEQ ID NO:5 spanning position(s) selected from the group consisting of:

- a) 1 to 200;
- b) 201 to 400;
- c) 401 to 600;
- d) 601 to 800;
- e) 801 to 1000;
- f) 1001 to 1200;
- g) 1201 to 1400;
- h) 1400 to 1629;
- i) 1694, wherein position 1694 is an asparagine;
- j) 1854, wherein position 1854 is a valine;
- k) 1967, wherein position 1967 is an asparagine;
- l) 2017, wherein position 2017 is a glutamic acid; and,
- m) 2050, wherein position 2050 is an alanine.

**Appl. No.** : 09/603,665  
**Filed** : June 23, 2000

68. (New) A polypeptide of claim 67, wherein said polypeptide is at least 100 amino acids in length and has an amino acid sequence comprising at least 10 contiguous amino acids of SEQ ID NO:5 spanning position(s) selected from the group consisting of:

- a) 1 to 200;
- b) 201 to 400;
- c) 401 to 600;
- d) 601 to 800;
- e) 801 to 1000;
- f) 1001 to 1200;
- g) 1201 to 1400;
- h) 1400 to 1629;
- i) 1694, wherein position 1694 is an asparagine;
- j) 1854, wherein position 1854 is a valine;
- k) 1967, wherein position 1967 is an asparagine;
- l) 2017, wherein position 2017 is a glutamic acid; and,
- m) 2050, wherein position 2050 is an alanine.

69. (New) A polypeptide of claim 68, wherein said polypeptide has an amino acid sequence comprising contiguous amino acids of SEQ ID NO:5 spanning position(s) selected from the group consisting of:

- a) 1 to 200;
- b) 201 to 400;
- c) 401 to 600;
- d) 601 to 800;

**Appl. No.** : 09/603,665  
**Filed** : June 23, 2000

- e) 801 to 1000;
- f) 1001 to 1200;
- g) 1201 to 1400; and,
- h) 1400 to 1629.

70. (New) A polypeptide of claim 65, wherein said polypeptide is recombinant.

71. (New) The composition of claim 65, further comprising a physiologically acceptable carrier.

72. (New) A method of making a polypeptide of claim 65 comprising the steps of:

- a) obtaining a cell capable of expressing said polypeptide;
- b) growing said cell under conditions suitable to produce said polypeptide; and
- c) isolating and purifying said polypeptide produced by said cell.

73. (New) The method of claim 72, wherein said cell is prokaryotic.

74. (New) The method of claim 72, wherein said cell is eukaryotic.

75. (New) A composition comprising an isolated and purified antibody, wherein said antibody specifically binds an epitope of a BAP28 polypeptide antigenic determinant, wherein said antigenic determinant comprises amino acids of SEQ ID NO:5 selected from the group consisting of:

- a) 1 to 200;
- b) 201 to 400;
- c) 401 to 600;

**Appl. No.** : 09/603,665  
**Filed** : June 23, 2000

- d) 601 to 800;
- e) 801 to 1000;
- f) 1001 to 1200;
- g) 1201 to 1400; and,
- h) 1400 to 1629.

76. (New) A method of binding the antibody of claim 75 with the antigenic determinant of claim 75, wherein said method comprises the steps of:

- a) obtaining a biological sample comprising the said polypeptide;
- b) obtaining a biological sample comprising said antibody;
- c) contacting said polypeptide with the antibody under conditions that allow specific binding of said antibody to said polypeptide; and,
- d) binding said antibody to said polypeptide.

77. (New) A composition comprising an isolated and purified antibody, wherein said antibody specifically binds an epitope of a BAP28 polypeptide antigenic determinant, wherein said epitope comprises at least one amino acid of SEQ ID NO:5 selected from the group consisting of:

- a) 1694, wherein position 1694 is an asparagine;
- b) 1854, wherein position 1854 is a valine;
- c) 1967, wherein position 1967 is an asparagine;
- d) 2017, wherein position 2017 is an glutamic acid; and,
- e) 2050, wherein position 2050 is an alanine.

78. (New) A method of binding the antibody of claim 77 to the epitope of claim 77, wherein said method comprises the steps of:

- a) obtaining a biological sample comprising the said polypeptide;